Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

FDA Approves Combination for Therapy-Related Acute Myeloid Leukemia

August 4, 2017
By Ian Ingram
News
Article

The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.

The approval covers therapy-related AML and AML with myelodysplasia-related changes

The US Food and Drug Administration (FDA) has approved a fixed combination of daunorubicin and cytarabine (Vyxeos, Jazz Pharmaceuticals) for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes. Patients with either of these types of AML have a very poor prognosis.

“This is the first approved treatment specifically for patients with certain types of high-risk AML,” said Richard Pazdur, MD, acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately.”

Therapy-related AML occurs in roughly 8% to 10% of cancer patients treated with radiation or chemotherapy, often within 5 years of treatment. AML with myelodysplasia-related changes is characterized by a history of blood disorders such as myelodysplastic syndromes or myeloproliferative neoplasms as well as other forms of AML with cytogenetic abnormalities or morphologic features.

The approval is based on data from a pivotal phase III trial that compared Vyxeos with cytarabine and daunorubicin (7 + 3) in 309 patients (ages 60 to 75 years) with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In the Vyxeos arm, patients received induction therapy of 44-mg daunorubicin and 100-mg/m2 cytarabine as a fixed combination administered intravenously over a 90-minute infusion on days 1, 3, and 5; and on days 1 and 3 if a second induction was needed. For consolidation, patients received a fixed combination of 29-mg daunorubicin and 65-mg/m2 cytarabine on days 1 and 3.

Patients in the 7 + 3 arm received induction therapy of 100-mg/m2 cytarabine each day intravenously on days 1–7 by continuous infusion and 60-mg/m2 daunorubicin each day on days 1–3. For consolidation, cytarabine was administered on days 1–5 and daunorubicin on days 1 and 2.

The median overall survival was 9.6 months in the Vyxeos arm vs 5.9 months in the 7 + 3 arm (hazard ratio, 0.69; 95% CI 0.52–0.90; P = .005). The complete response rate was also higher in the Vyxeos arm (38% vs 26%; P = .036).

Compared with patients in the 7 + 3 arm, all-cause 30-day mortality was improved in the Vyxeos arm (6% vs 11%), as was all-cause 60-day mortality (14% vs 21%). More patients in the Vyxeos arm were also able to receive hematopoietic stem cell transplant (34% vs 25%).

“Vyxeos is the first chemotherapy to demonstrate an overall survival advantage over the standard of care in a phase III randomized study of older adults with newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes,” said Jeffrey E. Lancet, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, in a press release from Jazz Pharmaceuticals. “The prognosis for these patients is poor, so the FDA approval of this new drug provides a welcome therapeutic advance.”

The most common (occurring in ≥ 25% of patients) adverse events seen in the trial were abdominal pain, arrhythmia, bacteremia, chills, constipation, cough, decreased appetite, diarrhea, dyspnea, edema, headache, hemorrhage, febrile neutropenia, fever, mucositis, musculoskeletal pain, nausea, pneumonia, rash, sleep disorders, and vomiting.

Six percent of patients in each arm of the trial had fatal adverse events on treatment or within 30 days of treatment that was not related to progressive disease. Patients taking Vyxeos should be monitored for decreased cardiac function and hypersensitivity reactions, and Vyxeos has also been associated with serious or fatal bleeding events.

Daunorubicin can leak from the vein or subcutaneous tissue and damage the skin.

Women who are either pregnant or breastfeeding should not take Vyxeos as it may cause harm to the fetus or newborn baby.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Related Content

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.